Enzystal-P pills, 20pcs

Composition

1 tablet, coated with an enteric coating contains:

Active ingredient:

pancreatin 116.17 mg

Pharmacological action

Enzistal-P is an enzyme agent.

Contains pancreatic enzymes-amylase, lipase and proteases, which facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine.

In diseases of the pancreas, it compensates for the insufficiency of its external secretory function and improves the digestive process.

Indications

• Insufficiency of external secretory function of the pancreas (including in chronic pancreatitis, cystic fibrosis).
• Chronic inflammatory and dystrophic diseases of the stomach, intestines, liver, and gallbladder; conditions after resection or irradiation of these organs, accompanied by impaired digestion, flatulence, and diarrhea (as part of combination therapy).
• To improve the digestion of food in patients with normal gastrointestinal function in case of errors in nutrition, as well as with violations of masticatory function, forced prolonged immobilization, sedentary lifestyle.
• Preparation for X-ray and ultrasound examination of the abdominal organs.

Use during pregnancy and lactation

The safety of pancreatin use during pregnancy has not been sufficiently studied. Use is possible in cases where the expected benefit to the mother exceeds the potential risk to the fetus.

In experimental studies, it was found that pancreatin does not have a teratogenic effect.

Use in children

Application is possible according to the dosage regimen. With high activity of lipase contained in pancreatin, the likelihood of developing constipation in children increases.

Contraindications

Acute pancreatitis, hypersensitivity to pancreatin.

Side effects

When used in medium therapeutic doses, the side effect is observed in less than 1%.

From the digestive system: in some cases-diarrhea, constipation, a feeling of discomfort in the stomach, nausea. A causal relationship between the development of these reactions and the action of pancreatin has not been established, since these phenomena relate to symptoms of external secretory pancreatic insufficiency.

Allergic reactions: in some cases – skin manifestations.

From the side of metabolism: with prolonged use in high doses, hyperuricosuria may develop, in excessively high doses-an increase in the level of uric acid in blood plasma.

Other: when using pancreatin in high doses in children, perianal irritation may occur.

Interaction

When used concomitantly with antacids containing calcium carbonate and/or magnesium hydroxide, the effectiveness of pancreatin may decrease.

With simultaneous use, it is theoretically possible to reduce the clinical effectiveness of acarbose.

With simultaneous use of iron preparations, iron absorption may decrease.

How to take, course of use and dosage

The dose (in terms of lipase) depends on the age and degree of pancreatic insufficiency. The average adult dose is 150,000 U/day. With complete insufficiency of the external secretory function of the pancreas-400,000 units/day, which corresponds to the daily need of an adult for lipase.

The maximum daily dose is 15,000 units/kg.

Children under 1.5 years of age – 50,000 units/day; older than 1.5 years-100,000 units/day.

The duration of treatment can vary from several days (if the digestive process is disrupted due to errors in the diet) to several months or even years (if permanent replacement therapy is required).

Special instructions

It is not recommended to use in the acute phase of chronic pancreatitis.

In cystic fibrosis, the dose should be adequate to the amount of enzymes needed for fat absorption, taking into account the quality and quantity of food consumed.

In cystic fibrosis, the use of pancreatin in doses greater than 10,000 U/kg/day (in terms of lipase) is not recommended due to the increased risk of strictures (fibrous colonopathy) in the ileocecal region and in the ascending colon.

With high activity of lipase contained in pancreatin, the likelihood of developing constipation in children increases. Increasing the dose of pancreatin in this category of patients should be carried out gradually.

Disorders of the digestive system may occur in patients with hypersensitivity to pancreatin, or in patients with a history of meconium ileus or intestinal resection.

Form of production

Enteric coated tablets

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Pancreatin

Dosage form

Tablets

Description

Children over 3 years of age, Pregnant women as prescribed by a doctor, Nursing mothers as prescribed by a doctor, For adults

Indications

Chronic pancreatitis, Flatulence, Preparation for ultrasound and X-ray of the abdominal cavity, Error in diet, Diarrhea, Overeating